Sign in

CIK 0001347178

  • Accelerated filer

Vanda Pharmaceuticals Inc.

Sign in to watch
Ticker
VNDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
030491827
Phone
+1 202-734-3400
Business address
2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
  1. 4 Grant or award Director acquired 5,000 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 4 Grant or award SVP & Chief Commercial Officer acquired 30,000 shares (grant or award)
  4. 4 Grant or award President and CEO acquired 200,000 shares (grant or award)
  5. 4 Grant or award EVP & Chief Financial Officer acquired 70,000 shares (grant or award)
  6. 4 Grant or award SVP, General Counsel & Sec. acquired 30,000 shares (grant or award)
  7. 5 Insider Annual Insider Trading Report
  8. 4 Open-market sale SVP & Chief Medical Officer sold 16,300 shares at $15.51 ($252,776)
  9. 4 Open-market sale SVP, General Counsel & Sec. sold 10,900 shares at $15.51 ($169,090)
  10. 4 Exercise or conversion SVP & Chief Commercial Officer acquired 20,000 shares (option exercise)
  11. 4 Open-market sale SVP, CFO & Treasurer sold 10,895 shares at $15.51 ($169,013)
  12. 4 Open-market sale President and CEO sold 23,330 shares at $15.48 ($361,242)
  13. 4 Open-market sale 10% owner sold 1,120,461 shares at an average $16.56 ($18,559,971)
  14. 4 Open-market sale 10% owner sold 547,886 shares at an average $15.66 ($8,582,621)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 12 of 29 · 579 filings